• About
• Links
• Contact
• Sitemap

Cancer Therapeutics 2006

Overview

Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry.

Arrowhead Publishers’ report entitled Cancer Therapeutics 2006: Market Dynamics and R&D Trends examines these four major cancer markets in light of newly emerging therapeutics, shifting market shares and line extensions for major products on the market.

Features of this Report

• market analysis by class, cancer type, product, company, and geographic region
• sales data from 2000 through Sept 2005 as well as full-year 2005 estimates
• profiles of leading products in the four major cancer markets and analysis of their market impact
• presentation and analysis of clinical data underscoring success of key therapies
• market share data for leading companies and products in the field
• SWOT analysis for key products in each market
• profiles of key emerging therapies and clinical data supporting development
• financial forecasts for the four major cancer markets
• 133 tables/graphs/diagrams illustrating historical sales data, growth rates and market share by product, class, therapeutic category, and company, company portfolios, pipelines, clinical efficacy data, as well as epidemiologic data

Additionally, Cancer Therapeutics 2006 offers readers a critical examination of emerging and pipeline products in colorectal, prostate, lung, and breast cancer. Pipeline products with the greatest potential are assessed for their clinical efficacy and possible market impact. Briefs are provided for companies that are either firmly entrenched in one of these four cancer markets or are developing groundbreaking new drugs that are being designed to treat not only one of the leading four cancers, but other cancers as well.

Table of Contents

• Table of Contents
• 1 Methodology and Executive Summary
  • 1.1 Report Objectives
  • 1.2 Research Methodology
  • 1.3 Executive Summary
  • 2 The Global Impact of Cancer
    • 2.1 United States
    • 2.2 The World
    • 2.3 Survival Rates
    • 2.4 Economic Impact
    • 2.5 Epidemiology of Select Cancers
      • 2.5.1 Colorectal Cancer
      • 2.5.2 Prostate Cancer
      • 2.5.3 Lung Cancer
      • 2.5.4 Breast Cancer
  • 3 Product, Company and Geographic Market Analysis
    • 3.1 Key Product Analysis
      • 3.1.1 The Top Three Oncology Products
      • 3.1.2 Fastest Growing Leading Therapies of 2005
      • 3.1.3 The Cytotoxic Market
      • 3.1.4 The Hormonal Market
      • 3.1.5 The Biologic/Targeted Therapies Market
    • 3.2 Key Company Market Analysis
      • 3.2.1 Sanofi Aventis
      • 3.2.2 Genentech/Roche
      • 3.2.3 AstraZeneca
      • 3.2.4 Pfizer
      • 3.2.5 Bristol-Myers Squibb
      • 3.2.6 Eli Lilly
      • 3.2.7 Takeda/TAP
  • 4 The Colorectal Cancer Therapy Market
    • 4.1 Current Treatment of Colorectal Cancer
      • 4.1.1 Surgery
      • 4.1.2 Radiation Therapy
      • 4.1.3 Cytotoxics
      • 4.1.4 Biologics
    • 4.2 An Overview of the Market for Colorectal Cancer Therapies
    • 4.3 Key Cytotoxics on the Market
      • 4.3.1 Eloxatin
        • 4.3.1.1 Market Impact
      • 4.3.2 Camptosar
        • 4.3.2.1 Market Impact
      • 4.3.3 Xeloda
        • 4.3.3.1 Market Impact
    • 4.4 Emerging Biologics with Strong Market Potential
      • 4.4.1 Avastin
        • 4.4.1.1 Market Impact
      • 4.4.2 Erbitux
        • 4.4.2.1 Market Impact
    • 4.5 Unmet Need in Colorectal Cancer Therapy
    • 4.6 Colorectal Cancer R & D Pipeline Analysis
      • 4.6.1 Key Products in Development
        • 4.6.1.1 Erbitux (Line Extension)
          • 4.6.1.1.1 Key Clinical Trials
        • 4.6.1.2 ABX-EGF
          • 4.6.1.2.1 Key Clinical Trials
        • 4.6.1.3 Avastin (Line Extension)
          • 4.6.1.3.1 Key Clinical Trials
        • 4.6.1.4 PTK/ZK
          • 4.6.1.4.1 Key Clinical Trials
      • 4.6.2 Vaccines: An Emerging Class
        • 4.6.2.1 Clinical Trial Strategies
        • 4.6.2.2 Clinical Trial Status of Key Product Candidates
        • 4.6.2.3 The Future of Colorectal Cancer Vaccines
    • 4.7 SWOT Analysis for Key Products in Colorectal Cancer Market
    • 4.8 The Outlook for Colorectal Cancer Therapy
    • 4.9 Financial Forecast
  • 5 The Prostate Cancer Therapy Market
    • 5.1 Current Treatment of Prostate Cancer
      • 5.1.1 Surgery
      • 5.1.2 Radiation Therapy
      • 5.1.3 Hormone Therapy
      • 5.1.4 Cytotoxics
    • 5.2 An Overview of the Market for Prostate Cancer Therapies
    • 5.3 Taxotere’s New Impact on the Market
    • 5.4 Other New Competition
    • 5.5 Unmet Need in Prostate Cancer Therapy
    • 5.6 Prostate Cancer R & D Pipeline Analysis
      • 5.6.1.1 Provenge
        • 5.6.1.1.1 Key Clinical Trials
      • 5.6.1.2 GVAX
        • 5.6.1.2.1 Key Clinical Trials
      • 5.6.1.3 Avastin (Line Extension)
        • 5.6.1.3.1 Key Clinical Trials
    • 5.7 SWOT Analysis for Key Products in Prostate Cancer Market
    • 5.8 The Outlook for Prostate Cancer Therapy
    • 5.9 Financial Forecast
  • 6 The Lung Cancer Therapy Market
    • 6.1 Current Treatment of Lung Cancer
      • 6.1.1 Surgery
      • 6.1.2 Cytotoxics
      • 6.1.3 Radiation Therapy
      • 6.1.4 First-Line Pharmaceutical Treatment of Lung Cancer
      • 6.1.5 Second-Line Pharmaceutical Treatment of Lung Cancer
    • 6.2 An Overview of the Market for Lung Cancer Therapies
      • 6.2.1 A Progress Report on New Targeted Therapies
        • 6.2.1.1 Iressa
        • 6.2.1.2 Tarceva
    • 6.3 Unmet Need in Lung Cancer Therapy
    • 6.4 Lung Cancer R&D Pipeline Analysis
      • 6.4.1 Key Products in Development
        • 6.4.1.1 Avastin (Line Extension)
          • 6.4.1.1.1 Key Clinical Trials
        • 6.4.1.2 Erbitux (Line Extension)
          • 6.4.1.2.1 Key Clinical Trials
        • 6.4.1.3 Zactima
          • 6.4.1.3.1 Key Clinical Trials
    • 6.5 SWOT Analysis for Key Products in Lung Cancer Market
    • 6.6 The Outlook for Lung Cancer Therapy
    • 6.7 Financial Forecast
  • 7 The Breast Cancer Therapy Market
    • 7.1 Current Treatment of Breast Cancer
      • 7.1.1 Surgery
      • 7.1.2 Radiation Therapy
      • 7.1.3 Hormonal Therapy
        • 7.1.3.1 Selective Estrogen Receptor Modulators (SERMs)
        • 7.1.3.2 Aromatase Inhibitors
        • 7.1.3.3 Estrogen Receptor Downregulators (ERDs)
        • 7.1.3.4 LHRH Analogs
      • 7.1.4 Cytotoxics
      • 7.1.5 Targeted Therapies
    • 7.2 An Overview of the Market for Breast Cancer Therapies
      • 7.2.1 Analysis of Key Products
        • 7.2.1.1 Taxotere
        • 7.2.1.2 Herceptin
        • 7.2.1.3 Arimidex
      • 7.2.2 Other New Approvals and Their Impact
    • 7.3 Unmet Need in Breast Cancer Therapy
    • 7.4 Breast Cancer R&D Pipeline Analysis
      • 7.4.1 Key Products in Development
        • 7.4.1.1 Lapatinib
          • 7.4.1.1.1 Key Clinical Trials
        • 7.4.1.2 Herceptin (Line Extension)
          • 7.4.1.2.1 Key Clinical Trials
        • 7.4.1.3 Femara (Line Extension)
          • 7.4.1.3.1 Key Clinical Trials
        • 7.4.1.4 Avastin (Line Extension)
          • 7.4.1.4.1 Key Clinical Trials
    • 7.5 SWOT Analysis for Key Products in Breast Cancer Market
    • 7.6 The Outlook for Breast Cancer Therapy
    • 7.7 Financial Forecast
  • 8 Company Briefs
• Abgenix
• Aeterna Zentaris
• Amgen
• Antigenics
• Antisoma
• Aphton Corp.
• AstraZeneca
• AVI Biopharma
• Biogen Idec
• Biomira
• Bristol-Myers Squibb
• Celgene
• Cell Genesys
• Chiron
• Dendreon
• Eli Lilly
• Genentech
• Genitope
• Genmab
• Genta
• Genzyme (Oncology)
• GlaxoSmithKline
• Hybridon
• Igeneon
• ImClone Systems
• Intracel Holdings Corp
• Lorus Therapeutics
• Medarex
• MedImmune
• Novartis
• Pfizer
• Roche
• Sanofi Aventis
• Schering
• Schering-Plough
• Seattle Genetics
• Therion Biologics
• Appendices
• Appendix I
• Cancer Therapeutics Pipeline
• Appendix II
• Coverage of Anti-Cancer Drugs for Off-Label Indications in Selected NCI Clinical Trials
• Appendix III
• Abbreviations
• Appendix IV
• Select Bibliography
• Tables
• Table 2.1 Estimated New Cancer Cases and Deaths, US 2005
• Table 2.2 Rates of Incidence and Deaths for Select Cancers Worldwide, 2000
• Table 2.3 Total Incidence of Cancer, by Region 2000
• Table 2.4 Five-Year Survival Rates for Select Cancers by Stage at Diagnosis, US 1995-2000
• Table 2.5 The Economic Impact of Cancer in the US
• Table 2.6 Global Lung Cancer Incidence in Select Regions, 2000
• Table 2.7 Breast Cancer Survival Rates, by Stage
• Table 2.8 Breast Cancer Overall Survival Rate
• Table 3.1 Sales of Top Oncology Drugs Indicated for Colorectal, Prostate, Lung, and Breast Cancers 2000-2005
• Table 3.2 Sanofi Aventis Key Oncology Product Sales 2000-2005
• Table 3.3 Sanofi Aventis Oncology Product Sales 2004, by Region/Country
• Table 3.4 Genentech/Roche Key Oncology Product Sales 2000-2005
• Table 3.5 AstraZeneca Key Oncology Product Sales 2000-2005
• Table 3.6 AstraZeneca Oncology Product Sales 2004, by Region/Country
• Table 3.7 Pfizer Key Oncology Product Sales 2000-2005
• Table 3.8 Pfizer Oncology Product Sales 2004, by Region/Country
• Table 3.9 Bristol-Myers Squibb Key Oncology Product Sales 2000-2005
• Table 3.10 Bristol-Myers Squibb Oncology Product Sales 2004, by Region/Country
• Table 3.11 Eli Lilly Key Oncology Product Sales 2000-2005
• Table 3.12 Eli Lilly Oncology Product Sales 2004, by Region/Country
• Table 3.13 Takeda/Tap Key Oncology Product Sales 2000-2005
• Table 3.14 Takeda/TAP Oncology Product Sales 2004, by Region/Country
• Table 4.1 The Stages of Colorectal Cancer
• Table 4.2 Common Treatments for Colorectal Cancer (Adjuvant, 1st-Line, and 2nd-Line)
• Table 4.3 Leading Drugs for Treatment of Colorectal Cancer 2000-2005
• Table 4.4 Sales of New Biologic Therapies for Colorectal Cancer 2004-2005
• Table 4.5 Sales of Eloxatin 2000-2005
• Table 4.6 Sales of Camptosar 2000-2005
• Table 4.7 Sales of Xeloda 2001-2005
• Table 4.8 Sales of Avastin 2004-2005
• Table 4.9 Sales of Erbitux 2004-2005
• Table 4.10 Colorectal Cancer Survival Rates and Role of Chemotherapy, by Stage
• Table 4.11 Key Colorectal Cancer Drugs in R&D Pipeline
• Table 4.12 A Look at Potential Colorectal Cancer Therapy Options in 2010
• Table 4.13 Colorectal Cancer Therapies Financial Forecast 2005-2010
• Table 5.1 Stages of Prostate Cancer
• Table 5.2 Best-Selling Hormone Therapies
• Table 5.3 Leading Drugs for Treatment of Prostate Cancer 2000-2005
• Table 5.4 Key Patent Expirations in Prostate Cancer Market
• Table 5.5 Taxotere vs Novantrone/prednisone in Hormone-refractory Prostate Cancer
• Table 5.6 Key Prostate Cancer Drugs in R&D Pipeline
• Table 5.7 Key Prostate Cancer Drugs in Development and Indications
• Table 5.8 Provenge Phase III Clinical Trial Results
• Table 5.9 Prostate Cancer Vaccines Sales Forecast 2006-2010
• Table 5.10 Prostate Cancer Therapy Financial Forecast 2005-2010
• Table 6.1 Types of Lung Cancer and Predominance
• Table 6.2 Stages of Lung Cancer
• Table 6.3 Diagnosis and Survival Rates for NSCLC in US
• Table 6.4 Clinical Trial Efficacy of Carboplatin-based Combinations vs Cisplatin-based Combinations
• Table 6.5 Common Platinum Combination Therapies
• Table 6.6 Key Second-Line Therapies for NSCLC
• Table 6.7 Clinical Efficacy Comparisons for 2nd Line Therapies for NSCLC
• Table 6.8 Leading Drugs for Treatment of Lung Cancer
• Table 6.9 Growth Rate of the Lung Cancer Therapy Market 2000-2005
• Table 6.10 Key Patent Expirations in Lung Cancer Market
• Table 6.11 Major Uses for Popular Anti-Cancer Agents
• Table 6.12 Sales of New Targeted Therapies for Lung Cancer 2002-2005
• Table 6.13 Epidermal Growth Factor (EGF) Receptor Inhibitor Clinical Trial Results
• Table 6.14 Key Lung Cancer Drugs in R&D Pipeline
• Table 6.15 Phase III Trials for Zactima
• Table 6.16 Lung Cancer Therapy Financial Forecast 2005-2010
• Table 7.1 Stages of Breast Cancer
• Table 7.2 Profiles of Key Aromatase Inhibitors on Market
• Table 7.3 Profiles of Single-Agent Chemotherapies for Metastatic Breast Cancer
• Table 7.4 Leading Drugs for Treatment of Breast Cancer
• Table 7.5 Growth Rate of the Breast Cancer Therapy Market 2000-2005
• Table 7.6 Major Uses for Popular Anti-Cancer Agents
• Table 7.7 Key Breast Cancer Drugs in R&D Pipeline
• Table 7.8 Femara vs Arimidex in Clinical Trial Results
• Table 7.9 Breast Cancer Therapy Market Growth 2005-2010
• Table 8.1 Clinical Development Status of Oncophage
• Table 8.2 AstraZeneca’s Oncology Portfolio
• Table 8.3 AstraZeneca’s Oncology Pipeline
• Table 8.4 Biogen Idec’s Oncology Pipeline
• Table 8.5 Biomira’s Vaccine Pipeline
• Table 8.6 Bristol-Myers Squibb’s Oncology Portfolio
• Table 8.7 Chiron’s Oncology Pipeline
• Table 8.8 Dendreon’s Vaccine Pipeline
• Table 8.9 Genentech’s Oncology Pipeline
• Table 8.10 GlaxoSmithKline’s Oncology Portfolio
• Table 8.11 GlaxoSmithKline’s Oncology Pipeline
• Table 8.12 Igeneon’s Oncology Pipeline
• Table 8.13 Potential Line Extensions for Erbitux
• Table 8.14 Medarex’s Oncology Pipeline
• Table 8.15 Medimmune’s Oncology Pipeline
• Table 8.16 Pfizer’s Late-Stage Oncology Pipeline
• Table 8.17 Roche’s Marketed Oncology Drugs
• Table 8.19 Schering-Plough’s Oncology Pipeline
• Table 8.18 Sanofi Aventis’ Cancer Pipeline
• Table 8.20 Therion’s Cancer Vaccine Pipeline
• Table I Cancer Therapeutics Pipeline
• Graphs
• Graph 2.1 Deadliest Cancers in the US 2005
• Graph 2.2 Leading Sites of New Cancer Cases, Male 2005
• Graph 2.3 Leading Sites of New Cancer Cases, Female 2005
• Graph 2.4 Regions Most Effected by Cancer 2000
• Graph 2.5 Global Prostate Cancer Incidence - Select Regions, 2000
• Graph 3.1 Value of Top Oncology Drugs Indicated for Colorectal, Prostate, Lung, and Breast Cancers 2000-2005
• Graph 3.2 Top 10 Oncology Products Indicated for Colorectal, Prostate, Lung and Breast Cancer, by Global Sales 2004-2005
• Graph 3.3 Top 10 Oncology Products Indicated for Colorectal, Prostate, Lung and Breast Cancer, by Growth Rate 2004-2005
• Graph 3.4 Value of the Cytotoxic Market 2000-2005, Colorectal, Prostate, Lung and Breast Cancer
• Graph 3.5 Value of the Hormonal Therapy Market 2000-2005, Prostateand Breast Cancer
• Graph 3.6 Value of the Biologic and Targeted Therapies Market 2000-2005, Colorectal, Prostate, Lung and Breast Cancer
• Graph 3.7 Oncology Portfolio Values of Major Stakeholders in Colorectal, Prostate, Lung, and Breast Cancers 2000-2005
• Graph 3.8 Key Company Market Share 2004 (Colorectal, Prostate, Lung and Breast
• Cancer Products)
• Graph 3.9 Key Company Market Share 2005, (Colorectal, Prostate, Lung and Breast
• Cancer Products)
• Graph 4.1 Value of the Colorectal Cancer Therapy Market, 2000-2005
• Graph 4.2 Colorectal Cancer Therapy Market, Cytotoxics vs. Biologics 2004-2005
• Graph 4.3 Key Colorectal Cancer Therapies Market Share 2004
• Graph 4.4 Key Colorectal Cancer Therapies Market Share 2005
• Graph 4.5 Key Colorectal Cancer Therapies in R&D, by Clinical Trial Phase and No. of Indications
• Graph 4.6 Colorectal Cancer Therapies Financial Forecast 2005-2010
• Graph 5.1 Value of the Prostate Therapy Market 2000-2005
• Graph 5.2 Key Prostate Cancer Therapies Market Share 2004
• Graph 5.3 Key Prostate Cancer Therapies Market Share 2005
• Graph 5.4 Key Prostate Cancer Therapies in R&D, by Clinical Trial Phase
• Graph 5.5 Prostate Cancer Vaccines Sales Forecast 2006-2010
• Graph 5.6 Prostate Cancer Therapy Financial Forecast 2005-2010
• Graph 6.1 Value of the Lung Cancer Therapy Market 2000-2005
• Graph 6.2 Key Lung Cancer Therapies Market Share 2004
• Graph 6.3 Key Lung Cancer Therapies Market Share 2005
• Graph 6.4 Lung Cancer Therapies in R&D, by Clinical Trial Phase
• Graph 6.5 Lung Cancer Therapy Financial Forecast 2005-2010
• Graph 7.1 Value of the Breast Cancer Therapy Market 2000-2005
• Graph 7.2 Breast Cancer Therapies Market Share 2004
• Graph 7.3 Breast Cancer Therapies Market Share 2005
• Graph 7.4 Hormonal Therapy Market Share 2004
• Graph 7.5 Hormonal Therapy Market Share 2005
• Graph 7.6 Cytotoxic Therapy Market Share 2004
• Graph 7.7 Cytotoxic Therapy Market Share 2005
• Graph 7.8 Breast Cancer Therapies in R&D, by Clinical Trial Phase
• Graph 7.9 Breast Cancer Therapy Financial Forecast 2005-2010
• Graph 8.1 Genentech’s Products with Additional Indication Pipelines, by Phase/number of Indications
• Diagrams
• Diagram I Treatment Options for Prostate Cancer, by Stage
•  

Other users found this report page using the following search terms: targeted therapy cytotoxic Antihormonal cancer oncology market prostate product schering therapeutics plough swot graphs

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.